Cosentyx is a biologic drug that is used to treat several inflammatory conditions, including psoriasis, psoriatic arthritis, and ankylosing spondylitis [1]. The active ingredient in Cosentyx is secukinumab, which works by blocking a protein called interleukin-17A (IL-17A) [2]. IL-17A is involved in the body's immune response and inflammation, which can contribute to these conditions.

There is no evidence to suggest that Cosentyx affects fertility. The drug's prescribing information does not mention any effects on fertility or reproductive function [1]. Additionally, a review of the available literature did not yield any studies or reports linking Cosentyx to fertility issues [3].

However, it is important to note that the safety of Cosentyx during pregnancy and breastfeeding is not well established. The drug is classified as a pregnancy category B medication, which means that animal studies have not shown any harm to the fetus, but there are no adequate studies in pregnant women [1]. It is also not known whether Cosentyx is excreted in human breast milk, so women who are breastfeeding should discuss the risks and benefits of the drug with their healthcare provider [2].

In summary, there is no evidence to suggest that Cosentyx affects fertility. However, the safety of the drug during pregnancy and breastfeeding is not well established, and women who are pregnant or breastfeeding should discuss the risks and benefits of the drug with their healthcare provider.

Sources:
[1] Drug Patent Watch. Cosentyx. Retrieved from https://www.drugpatentwatch.com/p/biologics/tradename/COSENTYX
[2] Versus Arthritis. Secukinumab. Retrieved from https://www.versusarthritis.org/about-arthritis/treatments/drugs/secukinumab/
[3] Medical News Today. What to know about Cosentyx. Retrieved from https://www.medicalnewstoday.com/articles/326632.